Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXLWOK)

Drug Name

11-deoxy-PGE2 Drug Info

Synonyms

11-deoxy-PGE2; 11-deoxy Prostaglandin E2; 9-oxo-15S-hydroxy-5Z,13E-prostadienoic acid; (Z)-7-[(1R,2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 11-Deoxyprostaglandin E2; 35536-53-9; LMFA03010061; AC1NR1FV; 11-deoxy-Prostaglandin E2; SCHEMBL9247000; GTPL1945; MolPort-039-138-850; HMS3648H09; ZINC27640133; 1151AH; SR-01000946427

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5283062
ChEBI ID: CHEBI:165301
CAS Number: CAS 35536-53-9
TTD Drug ID: DMXLWOK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Prostaglandin E2 receptor EP4 (PTGER4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[3]
RQ-00000007 (oral)	DMMYTRU	Pain	MG30-MG3Z	Phase 2	[4]
ONO-AE1-437	DMCUGI8	Asthma	CA23	Phase 2	[5]
BGC-20-1531	DMS2MQ5	Migraine	8A80	Phase 2	[6]
IK-007	DMBLFPN	Non-small-cell lung cancer	2C25	Phase 1/2	[7]
TPST-1495	DM3GSB2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
E7046	DMFVT43	Rectal adenocarcinoma	2B92	Phase 1	[9]
ONO-4232	DMO4SD2	Acute heart failure	BD10-BD13	Phase 1	[10]
ONO-4578	DME63VK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
AN0025	DMGSYPY	Aggressive cancer	2A00-2F9Z	Phase 1	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin E2 receptor EP4 (PTGER4)	TT79WV3	PE2R4_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1945).
2	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
3	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
4	Clinical pipeline report, company report or official report of Avarx.
5	An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
6	BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
7	Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9.
8	Clinical pipeline report, company report or official report of Tempest Therapeutics.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
11	AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669.